Emerging Role of VCP/p97 in Cardiovascular Diseases: Novel Insights and Therapeutic Opportunities

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2021 Jan 13

PMID 33439255

Citations 6

Authors

Hongyang Shu

Yizhong Peng

Weijian Hang

Ning Zhou

Dao Wen Wang

Affiliations

Soon will be listed here.

Abstract

Valosin-containing protein (VCP/p97) is a member of the conserved type II AAA+ (ATPases associated with diverse cellular activities) family of proteins with multiple biological functions, especially in protein homeostasis. Mutations in VCP/p97 are reportedly related to unique autosomal dominant diseases, which may worsen cardiac function. Although the structure of VCP/p97 has been clearly characterized, with reports of high abundance in the heart, research focusing on the molecular mechanisms underpinning the roles of VCP/p97 in the cardiovascular system has been recently undertaken over the past decades. Recent studies have shown that VCP/p97 deficiency affects myocardial fibers and induces heart failure, while overexpression of VCP/p97 eliminates ischemia/reperfusion injury and relieves pathological cardiac hypertrophy caused by cardiac pressure overload, which is related to changes in the mitochondria and calcium overload. However, certain studies have drawn opposing conclusions, including the mitigation of ischemia/reperfusion injury via inhibition of VCP/p97 ATPase activity. Nevertheless, these emerging studies shed light on the role of VCP/p97 and its therapeutic potential in cardiovascular diseases. In other words, VCP/p97 may be involved in the development of cardiovascular disease, and is anticipated to be a new therapeutic target. This review summarizes current findings regarding VCP/p97 in the cardiovascular system for the first time, and discusses the role of VCP/p97 in cardiovascular disease.

Citing Articles

The function of p97/valosin-containing protein (VCP) and small VCP-interacting protein (SVIP) in invasion and migration of pancreatic cancer cells.

Alimogullari E, Cayli S Turk J Med Sci. 2024; 54(5):1154-1164.

PMID: 39473740 PMC: 11518332. DOI: 10.55730/1300-0144.5894.

Personalized transcriptome signatures in a cardiomyopathy stem cell biobank.

Monte E, Furihata T, Wang G, Perea-Gil I, Wei E, Chaib H bioRxiv. 2024; .

PMID: 38798547 PMC: 11118309. DOI: 10.1101/2024.05.10.593618.

Baicalin alleviates angiotensin II-induced cardiomyocyte apoptosis and autophagy and modulates the AMPK/mTOR pathway.

Cheng Y, Yan M, He S, Xie Y, Wei L, Xuan B J Cell Mol Med. 2024; 28(9):e18321.

PMID: 38712979 PMC: 11075640. DOI: 10.1111/jcmm.18321.

CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes.

Yuan Q, Sun Y, Yang F, Yan D, Shen M, Jin Z Signal Transduct Target Ther. 2023; 8(1):99.

PMID: 36882410 PMC: 9992392. DOI: 10.1038/s41392-022-01306-2.

CRISPR/Cas9-Mediated Constitutive Loss of VCP (Valosin-Containing Protein) Impairs Proteostasis and Leads to Defective Striated Muscle Structure and Function In Vivo.

Voisard P, Diofano F, Glazier A, Rottbauer W, Just S Int J Mol Sci. 2022; 23(12).

PMID: 35743185 PMC: 9223409. DOI: 10.3390/ijms23126722.

References

Lizano P, Rashed E, Stoll S, Zhou N, Wen H, Hays T . The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo. Sci Rep. 2017; 7:46324. PMC: 5397870. DOI: 10.1038/srep46324. View

Xue L, Blythe E, Freiberger E, Mamrosh J, Hebert A, Reitsma J . Valosin-containing protein (VCP)-Adaptor Interactions are Exceptionally Dynamic and Subject to Differential Modulation by a VCP Inhibitor. Mol Cell Proteomics. 2016; 15(9):2970-86. PMC: 5013311. DOI: 10.1074/mcp.M116.061036. View

Chia W, Chia D, Rao F, Bar Nun S, Shochat S . ATP binding to p97/VCP D1 domain regulates selective recruitment of adaptors to its proximal N-domain. PLoS One. 2012; 7(12):e50490. PMC: 3513293. DOI: 10.1371/journal.pone.0050490. View

Bodnar N, Kim K, Ji Z, Wales T, Svetlov V, Nudler E . Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1-Npl4. Nat Struct Mol Biol. 2018; 25(7):616-622. PMC: 6044470. DOI: 10.1038/s41594-018-0085-x. View

Wu X, Rapoport T . Mechanistic insights into ER-associated protein degradation. Curr Opin Cell Biol. 2018; 53:22-28. PMC: 6131047. DOI: 10.1016/j.ceb.2018.04.004. View

Ritson G, Custer S, Freibaum B, Guinto J, Geffel D, Moore J . TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci. 2010; 30(22):7729-39. PMC: 2890254. DOI: 10.1523/JNEUROSCI.5894-09.2010. View

Nagahama M, Ohnishi M, Kawate Y, Matsui T, Miyake H, Yuasa K . UBXD1 is a VCP-interacting protein that is involved in ER-associated degradation. Biochem Biophys Res Commun. 2009; 382(2):303-8. DOI: 10.1016/j.bbrc.2009.03.012. View

Moir D, Stewart S, Osmond B, Botstein D . Cold-sensitive cell-division-cycle mutants of yeast: isolation, properties, and pseudoreversion studies. Genetics. 1982; 100(4):547-63. PMC: 1201831. DOI: 10.1093/genetics/100.4.547. View

Song C, Xiao Z, Nagashima K, Li C, Lockett S, Dai R . The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation. Toxicol Appl Pharmacol. 2008; 228(3):351-63. PMC: 2692476. DOI: 10.1016/j.taap.2007.12.026. View

10.

Wang T, Xu W, Qin M, Yang Y, Bao P, Shen F . Pathogenic Mutations in the Valosin-containing Protein/p97(VCP) N-domain Inhibit the SUMOylation of VCP and Lead to Impaired Stress Response. J Biol Chem. 2016; 291(27):14373-14384. PMC: 4933190. DOI: 10.1074/jbc.M116.729343. View

11.

Kimura Y, Fukushi J, Hori S, Matsuda N, Okatsu K, Kakiyama Y . Different dynamic movements of wild-type and pathogenic VCPs and their cofactors to damaged mitochondria in a Parkin-mediated mitochondrial quality control system. Genes Cells. 2013; 18(12):1131-43. DOI: 10.1111/gtc.12103. View

12.

Shende P, Xu L, Morandi C, Pentassuglia L, Heim P, Lebboukh S . Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc Res. 2015; 109(1):103-14. DOI: 10.1093/cvr/cvv252. View

13.

Gallagher P, Clowes Candadai S, Gardner R . The requirement for Cdc48/p97 in nuclear protein quality control degradation depends on the substrate and correlates with substrate insolubility. J Cell Sci. 2014; 127(Pt 9):1980-91. PMC: 4004975. DOI: 10.1242/jcs.141838. View

14.

Eltzschig H, Eckle T . Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011; 17(11):1391-401. PMC: 3886192. DOI: 10.1038/nm.2507. View

15.

Kimonis V, Fulchiero E, Vesa J, Watts G . VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta. 2008; 1782(12):744-8. DOI: 10.1016/j.bbadis.2008.09.003. View

16.

Asanuma H, Kitakaze M . Does the treatment of both hypertension and cardiac hypertrophy not only prevent but also treat acute myocardial infarction?. Circ J. 2011; 75(5):1061-2. DOI: 10.1253/circj.cj-11-0292. View

17.

MacRae C, Roden D, Loscalzo J . The Future of Cardiovascular Therapeutics. Circulation. 2016; 133(25):2610-7. DOI: 10.1161/CIRCULATIONAHA.116.023555. View

18.

Ide Y, Horie T, Saito N, Watanabe S, Otani C, Miyasaka Y . Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction. JACC Basic Transl Sci. 2019; 4(6):701-714. PMC: 6834964. DOI: 10.1016/j.jacbts.2019.06.001. View

19.

Bodnar N, Rapoport T . Toward an understanding of the Cdc48/p97 ATPase. F1000Res. 2017; 6:1318. PMC: 5543420. DOI: 10.12688/f1000research.11683.1. View

20.

Lizano P, Rashed E, Kang H, Dai H, Sui X, Yan L . The valosin-containing protein promotes cardiac survival through the inducible isoform of nitric oxide synthase. Cardiovasc Res. 2013; 99(4):685-93. PMC: 3746953. DOI: 10.1093/cvr/cvt136. View